MedTrace Logo

Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome

NCT01107964 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-12-22

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

Oral Omega-3-acid ethyl esters

1 gram capsule by mouth four times daily for 45 days

DRUG

Placebo corn oil capsule

1 gram by mouth 4 times daily for 45 days

Sponsors & Collaborators

  • The American Society of Cataract and Refractive Surgery Foundation

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • David Liang, MD · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-08-31
Completion
2015-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01107964 on ClinicalTrials.gov